Theraclone Raises $1.5M

3/19/10

Theraclone Sciences, the Seattle-based developer of antibody drugs, has raised another $1.5 million in equity financing, according to a regulatory filing. The new equity comes after Theraclone received $29 million in venture capital in March 2007 from Arch Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Equities. The company also has funding for its HIV research and development from the International AIDS Vaccine Initiative and Japan-based Zenyaku Kogyo.

By posting a comment, you agree to our terms and conditions.